Transforming Growth Factor-β Signaling Guides the Differentiation of Innate Lymphoid Cells in Salivary Glands

被引:197
|
作者
Cortez, Victor S. [1 ]
Cervantes-Barragan, Luisa [1 ]
Robinette, Michelle L. [1 ]
Bando, Jennifer K. [1 ]
Wang, Yaming [1 ]
Geiger, Theresa L. [2 ]
Gilfillan, Susan [1 ]
Fuchs, Anja [3 ]
Vivier, Eric [4 ]
Sun, Joe C. [2 ]
Cella, Marina [1 ]
Colonna, Marco [1 ]
机构
[1] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA
[2] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10065 USA
[3] Washington Univ, Sch Med, Dept Surg, Sect Acute & Crit Care Surg, St Louis, MO 63108 USA
[4] UM2 Aix Marseille Univ, Ctr Immunol Marseille Luminy, Marseille, France
关键词
MEMORY T-CELLS; TGF-BETA; TRANSCRIPTIONAL REGULATION; NFIL3; EXPRESSION; INDUCTION; INFECTION; EFFECTOR; ISOFORMS; LIVER;
D O I
10.1016/j.immuni.2016.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The signals guiding differentiation of innate lymphoid cells (ILCs) within tissues are not well understood. Salivary gland (SG) ILCs as well as liver and intestinal intraepithelial ILC1 have markers that denote tissue residency and transforming growth factor-beta (TGF-beta) imprinting. We deleted Tgfbr2 in cells expressing the ILC and NK marker NKp46 and found that SG ILCs were reduced in number. They lost distinct tissue markers, such as CD49a, and the effector molecules TRAIL and CD73. Expression of the transcription factor Eomes, which promotes NK cell differentiation, was elevated. Conversely, Eomes deletion in NKp46(+) cells enhanced TGF-beta-imprinting of SG ILCs. Thus, TGF-beta induces SG ILC differentiation by suppressing Eomes. TGF-beta acted through a JNK-dependent, Smad4-independent pathway. Transcriptome analysis demonstrated that SG ILCs had characteristic of both NK cells and ILC1. Finally, TGF-beta imprinting of SG ILCs was synchronized with SG development, highlighting the impact of tissue microenvironment on ILC development.
引用
收藏
页码:1127 / 1139
页数:13
相关论文
共 50 条
  • [41] Transforming growth factor-β signaling in normal and malignant Hematopoiesis
    Isufi, Iris
    Seetharam, Mahesh
    Zhou, Li
    Sohal, Davendra
    Opalinska, Joanna
    Pahanish, Perry
    Verma, Amit
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2007, 27 (07): : 543 - 552
  • [42] Transforming growth factor-β signaling in normal and malignant hematopoiesis
    S-J Kim
    J Letterio
    Leukemia, 2003, 17 : 1731 - 1737
  • [43] Abrogation of Transforming Growth Factor-β Signaling in Pancreatic Cancer
    Xia Lin
    Xin-Hua Feng
    World Journal of Surgery, 2005, 29 : 312 - 316
  • [44] Transforming growth factor-β signaling in breast cancer subtypes
    Ganapathy, Vidya
    Reiss, Michael
    CANCER RESEARCH, 2010, 70
  • [45] Transforming Growth Factor-β Signaling Pathway Activation in Keratoconus
    Engler, Christoph
    Chakravarti, Shukti
    Doyle, Jefferson
    Eberhart, Charles G.
    Meng, Huan
    Stark, Walter J.
    Kelliher, Clare
    Jun, Albert S.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2011, 151 (05) : 752 - 759
  • [46] Transforming growth factor-β signaling in cancer invasion and metastasis
    Leivonen, Suvi-Katri
    Kahari, Veli-Matti
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (10) : 2119 - 2124
  • [47] Transforming growth factor-β signaling and its role in cancer
    Souchelnytskyi, S
    EXPERIMENTAL ONCOLOGY, 2002, 24 (01) : 3 - 12
  • [48] Deferoxamine synergizes with transforming growth factor-β signaling in chondrogenesis
    Huang, Zheng
    He, Guangxu
    Huang, Yanke
    GENETICS AND MOLECULAR BIOLOGY, 2017, 40 (03) : 698 - 702
  • [49] Transforming growth factor-β and myostatin signaling in skeletal muscle
    Kollias, Helen D.
    McDermott, John C.
    JOURNAL OF APPLIED PHYSIOLOGY, 2008, 104 (03) : 579 - 587
  • [50] Regulation of transforming growth factor-β signaling and vascular diseases
    Miyazono, K
    CORNEA, 2002, 21 (07) : S48 - S53